| http://purl.uniprot.org/citations/16757681 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/16757681 | http://www.w3.org/2000/01/rdf-schema#comment | "Human CD32B (FcgammaRIIB), the low-affinity inhibitory receptor for IgG, is the predominant Fc receptor (FcR) present on B cells. Immunohistochemical and expression studies have identified CD32B expression in a variety of B-cell malignancies, suggesting that CD32B is a potential immunotherapeutic target for B-cell malignancies. A high-affinity monoclonal antibody (mAb 2B6), from a novel panel of anti-human CD32B-specific mAbs, was chimerized (ch2B6) and humanized (hu2B6-3.5). Both ch2B6 and hu2B6-3.5 were capable of directing cytotoxicity by peripheral blood mononuclear cells and monocyte-derived macrophages against B-lymphoma lines in vitro. In a human B-cell lymphoma mouse xenograft model, administration of ch2B6 or hu2B6-3.5 reduced tumor growth rate and improved tumor-free survival. Both the in vitro and in vivo activities of 2B6 required an intact Fc, suggesting an FcR-mediated mechanism of action. These data support the hypothesis that CD32B is a viable target for mAb treatment of B-cell lymphoproliferative disorders."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.org/dc/terms/identifier | "doi:10.1182/blood-2006-05-020602"xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Huang L."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Johnson S."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Li H."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Thomas S."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Koenig S."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Burke S."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Rankin C.T."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Stavenhagen J."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Bonvini E."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Veri M.C."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Tuaillon N."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Inzunza H.D."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/author | "Gorlatov S."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/date | "2006"xsd:gYear |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/name | "Blood"xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/pages | "2384-2391"xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/title | "CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma."xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://purl.uniprot.org/core/volume | "108"xsd:string |
| http://purl.uniprot.org/citations/16757681 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/16757681 |
| http://purl.uniprot.org/citations/16757681 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/16757681 |
| http://purl.uniprot.org/uniprot/#_A0A0B4J1E6-mappedCitation-16757681 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16757681 |
| http://purl.uniprot.org/uniprot/#_A0A0B4J1G1-mappedCitation-16757681 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/16757681 |